Inflammation-based prognostic system predicts survival after surgery for stage IV colorectal cancer

American Journal of Surgery

Volumn 205, Issue 1, 2013, Pages 22-28

  Ishizuka, Mitsuru ^a   Nagata, Hitoshi ^a   Takagi, Kazutoshi ^a   Iwasaki, Yoshimi ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Glasgow prognostic score; Postoperative survival; Stage IV colorectal cancer; Subclass; Systemic inflammatory response

Indexed keywords

C REACTIVE PROTEIN;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SCORING SYSTEM;

AGED; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPOALBUMINEMIA; INFLAMMATION; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84871248033     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2012.04.012     Document Type: Article

References (36)

1. T. André, C. Boni, L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351 (Pubitemid 38702845)
2. L.B. Saltz, D. Niedzwiecki, D. Hollis Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 J Clin Oncol 25 2007 3456 3461 (Pubitemid 47310883)
3. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
4. E. Van Cutsem, C.H. Köhne, E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
5. D.C. McMillan, K. Canna, C.S. McArdle Systemic inflammatory response predicts survival following curative resection of colorectal cancer Br J Surg 90 2003 215 219 (Pubitemid 36237897)
6. L.M. Forrest, D.C. McMillan, C.S. McArdle Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer Br J Cancer 90 2004 1704 1706 (Pubitemid 38725637)
7. A.M. Al Murri, J.M. Bartlett, P.A. Canney Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer Br J Cancer 94 2006 227 230 (Pubitemid 43151540)
8. D.J. Brown, R. Milroy, T. Preston The relationship between an inflammation-based prognostic score (Glasgow prognostic score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer J Clin Pathol 60 2007 705 708 (Pubitemid 46975230)
9. S. Ramsey, G.W. Lamb, M. Aitchison Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer Cancer 109 2007 205 212 (Pubitemid 46106235)
10. K. Canna, P.A. McArdle, D.C. McMillan The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer Br J Cancer 92 2005 651 654 (Pubitemid 40460599)
11. K.A. Kwon, S.H. Kim, S.Y. Oh Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer BMC Cancer 10 2010 203
12. H. Knüpfer, R. Preiss Serum interleukin-6 levels in colorectal cancer patients-a summary of published results Int J Colorectal Dis 25 2010 135 140
13. T. Nozoe, T. Matsumata, K. Sugimachi Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer Am J Clin Oncol 23 2000 263 266 (Pubitemid 32428031)
14. C. Miki, N. Konishi, E. Ojima C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma Dig Dis Sci 49 2004 970 976 (Pubitemid 39012280)
15. D.C. McMillan, W.S. Watson, P. O'Gorman Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss Nutr Cancer 39 2001 210 213 (Pubitemid 33694037)
16. G. Folprecht, A. Grothey, S. Alberts Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates Ann Oncol 16 2005 1311 1319 (Pubitemid 41158476)
17. R. Adam, V. Delvart, G. Pascal Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 2004 644 657
18. M. Ishizuka, H. Nagata, K. Takagi Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer Ann Surg 250 2009 268 272
19. R. Sharma, M. Zucknick, R. London Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer Clin Colorectal Cancer 7 2008 331 337
20. J.Y. Wang, C.Y. Lu, K.S. Chu Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer Eur Surg Res 39 2007 245 250 (Pubitemid 47000372)
21. W. Reiter, P. Stieber, C. Reuter Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer Anticancer Res 20 2000 5195 5198 (Pubitemid 32319106)
22. L.M. Forrest, D.C. McMillan, C.S. McArdle A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer Br J Cancer 92 2005 1834 1836 (Pubitemid 40826128)
23. W. Reiter, P. Stieber, C. Reuter Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma Anticancer Res 17 1997 2935 2938 (Pubitemid 27434824)
24. M. Ishizuka, K. Kubota, J. Kita Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma J Surg Oncol 103 2011 801 806
25. E.F. Leitch, M. Chakrabarti, J.E. Crozier Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer Br J Cancer 97 2007 1266 1270 (Pubitemid 350035815)
26. M.J. Proctor, D.S. Morrison, D. Talwar A comparison of inflammation-based prognostic scores in patients with cancer A Glasgow inflammation outcome study Eur J Cancer 47 2011 2633 2641
27. D.C. McMillan, J.E. Crozier, K. Canna Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer Int J Colorectal Dis 22 2007 881 886 (Pubitemid 46952036)
28. L.M. Forrest, D.C. McMillan, C.S. McArdle A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer Br J Cancer 92 2005 1834 1836 (Pubitemid 40826128)
29. A.B. Crumley, D.C. McMillan, M. McKernan Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer Br J Cancer 94 2006 637 641 (Pubitemid 43361893)
30. A.B. Crumley, J.J. Going, M. Hilmy Interrelationships between tumor proliferative activity, leucocyte and macrophage infiltration, systemic inflammatory response, and survival in patients selected for potentially curative resection for gastroesophageal cancer Ann Surg Oncol 18 2011 2604 2612
31. S. Benoist, A. Brouquet, C. Penna Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24 2006 3939 3945 (Pubitemid 46630742)
32. B. Nordlinger, H. Sorbye, B. Glimelius Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial Lancet 371 2008 1007 1016 (Pubitemid 351392040)
33. L.B. Saltz, S. Clarke, E. Díaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
34. D. Ribero, H. Wang, M. Donadon Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 2007 2761 2767 (Pubitemid 350250347)
35. H. Bismuth, R. Adam, F. Lévi Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy Ann Surg 224 1996 509 520
36. R. Adam, E. Avisar, A. Ariche Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal Ann Surg Oncol 8 2001 347 353 (Pubitemid 32422861)